Use of Immune Regulation in HNSCC

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Chewei Wang	--	2600	2024-03-08 23:59:25	\|
2	format	Jason Zhu	Meta information modification	2605	2024-03-12 03:12:37	\|

This entry is adapted from the peer-reviewed paper 10.3390/cells13050413

Immunotherapy has emerged as a promising new treatment modality for head and neck cancer, offering the potential for targeted and effective cancer management. Squamous cell carcinomas pose significant challenges due to their aggressive nature and limited treatment options. Conventional therapies such as surgery, radiation, and chemotherapy often have limited success rates and can have significant side effects. Immunotherapy harnesses the power of the immune system to recognize and eliminate cancer cells, and thus represents a novel approach with the potential to improve patient outcomes. In the management of head and neck squamous cell carcinoma (HNSCC), important contributions are made by immunotherapies, including adaptive cell therapy (ACT) and immune checkpoint inhibitor therapy.

head and neck squamous cell carcinoma

1. Immune Checkpoint Inhibitor-Based Therapeutics in HNSCC

1.1. Targeting PD-1/PD-L1

The use of PD-1/PD-L1 targeting monoclonal antibodies to counteract the immunosuppressive role of PD-1 could help maintain a robust T-cell response against tumor cells ^[1] (Figure 1). The USA FDA has approved five monoclonal antibodies targeting PD-1 and PD-L1. Two of them target PD-L1, Atezolizumab, and Durvalumab, while Nivolumab, Pembrolizumab, and Cemiplimab are against PD-1. Nivolumab and Pembrolizumab are approved for patients with relapsed or metastatic cisplatin-resistant HNSCC ^[2], whereas Cemiplimab exhibits significant responses in patients with metastatic cutaneous squamous cell carcinoma ^[3].

Figure 1. Action mechanisms of antibodies targeting PD-1, PD-L1, and CTLA-4. Immune checkpoint proteins PD-1 and PD-L1 are expressed in T cells, B cells, and antigen-presenting cells (APCs). High levels of PD-L1 expression hide cancer cells from T cells and enable them to grow unchecked. When PD-1 binds to PD-L1, T cells stop dividing and killing cancer cells. Through activation of PD-1/PD-L1 signaling, cancer cells evade immune responses. Inhibition of the PD-1/PD-L1 interaction by monoclonal antibodies overturns this process and augments activity. This allows T cells to become activated and kill cancer cells. This figure was created with BioRender.com (accessed on 10 October 2023).

Nivolumab is an IgG4 monoclonal antibody that acts as an anti-PD-1 agent and blocks co-suppressive signals via the PD-1/PD-L1 signaling pathway. It was a significant milestone as the first FDA-approved immunotherapy for patients with HNSCC, based on the results of a Phase III clinical trial known as CheckMate 141 (NCT02105636) ^[4]. The study involved 361 participants with recurrent HNSCC who had experienced progression 6 months after platinum chemotherapy. These individuals were divided into two groups in a 2:1 ratio, with one group receiving nivolumab and the other receiving standard systemic drug therapy with methotrexate, docetaxel, or cetuximab every two weeks. The primary endpoint of the study was overall survival (OS), while secondary objectives were objective response, progression-free survival (PFS), safety, and patient-reported quality of life ^[5]. The study results showed that the group treated with nivolumab survived for a median of 7.5 months, while the standard treatment group achieved survival of 5.1 months. The estimated one-year survival rates for the nivolumab and standard treatment groups were approximately 36.0% and 16.6%, respectively. At 6 months, the PFS rate was 19.7% in the nivolumab group, compared with 9.9% in the standard treatment group. Furthermore, the incidence of severe adverse effects (grade III or IV) was lower in the nivolumab group (13.1%) compared to the standard treatment group (35.1%) ^[4].

Pembrolizumab is a humanized IgG4-κ monoclonal antibody with a high affinity for PD-1. It received its first FDA approval in 2017 following results from the phase Ib cohort expansion study, KEYNOTE 012 ^[6]. Importantly, in advanced HNSCC patients, treatments with pembrolizumab have shown high survival rates (6-month OS rate: 58%; and 12-month OS rate: 38%) and no adverse event-related deaths, an outcome rarely seen with existing cytotoxic or targeted therapies ^[7].

The comparison between pembrolizumab and standard treatment has been made in KEYNOTE 040 to validate that it prolongs the median OS to 8.4 months from 6.9 months for HNSCC patients ^[8]. In addition, a phase III clinical trial called KEYNOTE 048 evaluated the use of pembrolizumab for the treatment of relapsed or metastatic HNSCC and reported significantly improved treatment outcomes with pembrolizumab in 2019. In an interim analysis, the combination of pembrolizumab and chemotherapy was found to result in longer OS than the combination of cetuximab and chemotherapy (13.0 months vs. 10.7 months) in the general patient population. Based on these compelling efficacy and safety results, pembrolizumab plus chemotherapy has become the primary treatment option for patients with recurrent or metastatic HNSCC. However, pembrolizumab monotherapy has become the first-line treatment for patients with recurrent or metastatic PD-L1⁺ HNSCC ^[9].

Emerging data have suggested that PD-L2 is an alternative ligand for PD-1, especially in PD-L1-negative patients. The interaction between PD-1 and PD-L2 exhibits a strong suppression of T cell receptor (TCR)-expressed proliferation and a reduction of cytokine production such as IL-4, IL-10, and INF-γ by CD4⁺ T cells. Moreover, the expression and function of PD-L2 appear to be comparable to PD-L1 and both can reduce PD-1 signaling affecting T-cell proliferation ^[10]. In addition, Yearley et al. used a unique immunohistochemistry assay to investigate the expression of PD-L2 in tumor tissues and the correlation between clinical response and PD-L2 status in tumor tissues from patients with relapsed/metastatic (R/M) HNSCC treated with pembrolizumab. The results indicated that there was a highly significant association between PD-L2 and PD-L1 in these tumors (p < 0.0001) ^[11]. However, PD-L2 expression was also detected in tumors without PD-L1 expression, suggesting that the predictive potential of PD-L2 is not dependent on PD-L1 ^[12].

Atezolizumab is an anti-PD-L1 monoclonal antibody that blocks PD-L1 and generates an anti-cancer immune response by blocking PD-L1 ^[13]. In 2014, it was used against HNSCC and other tumor types such as NSCLC, melanoma, gastric cancer, colorectal cancer, and pancreatic cancer to investigate safety and tolerability. This first Phase I study (PCD4989g; NCT01375842) did not follow the traditional clinical trial design ^[14]. Later, in 2018, A. D. Colevas et. al. reported on the safety and long-term efficacy of atezolizumab as a single agent in a Phase Ia clinical trial in patients with HNSCC. This Phase Ia study involved 32 patients in whom treatment-related adverse events (TRAEs) of varying grades, including grades 1, 2, 3, and 4, were observed. There were no deaths and no grade 5 TRAEs. Overall survival was 6.0 months with good tolerability of atezolizumab ^[15].

Cemiplimab is an IgG4 monoclonal antibody with high affinity and dynamics against PD-1. A study in 2018 has shown that cemiplimab is effective in reducing tumors in the phase I advanced cutaneous squamous cell carcinoma (CSCC) expansion cohort (NCT02383212) and the metastatic cohort of the phase II trial (NCT02760498) ^[16]. Furthermore, cemiplimab is reported to exhibit marked anti-tumor activity with a fixed dose (350 mg intravenously every 3 weeks), and durable long-term effects (3 mg/kg intravenously every 2 weeks) in metastatic CSCC (NCT02760498) ^[17].

Durvalumab is a monoclonal antibody that directly engages with PD-L1 with high affinity and, as a result, blocks the interaction with PD-1 and CD80. In the HAWK Phase II study, it was administered to individuals with recurrent and/or metastatic HNSCC who had PD-L1 expression in more than 25% of tumor cells after unsuccessful platinum-based chemotherapy ^[18].

1.2. Targeting CTLA-4

Ipilimumab is a monoclonal antibody (mAb) targeting CTLA-4 (Figure 1) that has been approved by the FDA for the treatment of metastatic melanoma. However, there are significant concerns about potential serious toxicity, including life-threatening colitis. Ongoing clinical trials are evaluating the use of ipilimumab in combination with cetuximab and intensity-modulated radiotherapy (IMRT) in patients with advanced HNSCC (NCT01860430 and NCT01935921). Concurrently, a phase I study is ongoing to evaluate the safety and optimal dosing of MGA271 (also known as enoblituzumab), a humanized mAb targeting CD276 (B7-H3), in combination with ipilimumab. This includes patients with B7-H3-expressing solid tumors, including HNSCC (NCT02381314). Another anti-CTLA4 antibody, tremelimumab, is also being studied in clinical trials in combination with the anti-PD-L1 antibody, durvalumab ^[1]. A randomized phase II clinical trial with 267 R/M HNSCC patients showed that the combination of durvalumab and tremelimumab resulted in clinically relevant overall survival and manageable toxic effects ^[19]. The clinical trial CheckMate 651 (NCT02823574) comprehensively demonstrated that a combination of nivolumab and ipilimumab is an excellent disease control agent in R/M HNSCC, increasing the median OS from 13.5 to 13.9 months compared to the EXTREME therapy ^[20].

1.3. Targeting GITR

AMG 228 is a human IgG1 monoclonal antibody that acts as an agonist by binding to human GITR, a molecule expressed by regulatory T cells. In a phase I study (NCT02437916), 30 patients were selected with advanced solid tumors, including colorectal cancer, HNSCC, urothelial transitional cell carcinoma, non-small cell lung cancer (NSCLC), and melanoma. They administered AMG 228 intravenously every 3 weeks. By employing a two-stage dose escalation strategy: first, a single patient cohort received 3, 9, 30, or 90 mg, followed by a “rolling 6” design involving two to six patients till the maximum tolerated dose or an elevated planned dose of 1200 mg was reached. The primitive focus of the study was to estimate the safety, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) based on the patients’ responses. The outcomes of the study concluded that within this patient population, AMG 228 was well tolerated up to 1200 mg. No dose-limiting toxicity (DLT) was observed, and the highest administered dose did not reach the maximum tolerated dose (MTD). However, there was no observable evidence of T-cell activation or any antitumor activity following a single administration of AMG 228 therapy ^[21].

2. Combined Immune Checkpoint Inhibitor Therapy in Oral Cancer

2.1. PD-1/CTLA-4 Combination

The immune checkpoint inhibitors that have been used alone/combined or in combination with other therapies are listed in Table 1. In a documented clinical case report, an unprecedented approach involving the combination of the anti-PD-1 antibody nivolumab and the anti-CTLA4 antibody ipilimumab was administered to a surgical patient diagnosed with HNSCC. Following, a 3-week course of treatment with these combined drugs, a computed tomography examination revealed a positive response in the patient’s cancer condition. However, subsequent magnetic resonance imaging (MRI) showed local recurrence at 7 months after the combined treatment. Notably, the expression levels of PD-L1 and CTLA-4 exhibited significant decreases at the cervical lymph node, whereas no substantial alteration was observed in the expression level of PD-L2 or the quantities of various immune cells, including B-cells, T-cells, T helper (Th) cells, cytotoxic and regulatory T lymphocytes, and NK cells ^[22]. This case report suggests that combined PD-1/CTLA-4 immune checkpoint inhibitor therapy may be effective in some patients with HNSCC, but further research is needed to confirm its efficacy and safety. More research is also needed to understand why the patient’s cancer recurred despite decreases in the expression levels of PD-L1 and CTLA-4.

Table 1. List of completed ICIs clinical trials for the treatment of head and neck cancers.

Serial	ICIs	Target	Phase	Arm/Group	No. of Patients	Combination	Clinical Trial Number	Primary Endpoint	Study Start/Date
1	Durvalumab	PD-L1	I	Recurrent and/or metastatic head and neck squamous cell carcinoma	71	Tremelimumab	NCT02262741	Safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity	15/10/2014
2	Pembrolizumab	PD-1	II	Recurrent and/or metastatic head and neck squamous cell carcinoma	172	After platinum-based and cetuximab therapy	NCT02255097	Objective response rate (ORR)	24/10/2014
3	Durvalumab	PD-L1	I/II	Head and neck cancer solid tumors	176	Epacadostat	NCT02318277	Safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy	05/01/2015
4	Pembrolizumab	PD-1	III	First-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma	882	Chemotherapy	NCT02358031	Progression-free survival (PFS)	19/03/2015
5	Pembrolizumab	PD-1	II	Advanced head and neck squamous cell carcinoma	78	Acalabrutinib	NCT02454179	Overall response rate (ORR)	01/05/2015
6	Nivolumab	PD-1	II	Metastatic head and neck squamous cell carcinoma (HNSCC)	65	Stereotactic body radiotherapy (SBRT)	NCT02684253	Best overall response (BOR)	11/02/2016
7	Pembrolizumab	PD-1	I/II	Locally advanced laryngeal squamous cell carcinoma (Grade 3/4)	9	Chemotherapy	NCT02759575	Adverse effects	01/04/2016
8	Pembrolizumab	PD-1	I	Recurrent and/or metastatic head and neck squamous cell carcinoma	36	Talimogene laherparepvec	NCT02626000	Safety and toxicity	06/04/2016
9	Nivolumab	PD-1	I	Intermediate and high-risk local regionally advanced head and neck cancer	40	Chemotherapy	NCT02764593	Safety	01/06/2016
10	Nivolumab	PD-1	II	Recurrent or metastatic squamous cell carcinoma	425	Ipilimumab	NCT02823574	Overall response rate (ORR)	08/11/2016
11	Nivolumab	PD-1	I/II	Neoadjuvant to surgery in advanced stage head and neck squamous cell carcinoma (HNSCC)	33	Ipilimumab	NCT03003637	Feasibility and safety	28/02/2017
12	Nivolumab	PD-1	II	Recurrent or metastatic salivary gland carcinoma	98	-	NCT03132038	Progression-free survival (PFS): after 6 months of treatment	24/03/2017
13	Nivolumab	PD-1	III	Recurrent and/or metastatic head and neck squamous cell carcinoma	124	-	NCT05802290	Adverse effects	27/11/2017
14	Nivolumab	PD-1	III	Locally advanced squamous cell carcinoma	74	Cisplatin in combination with radiotherapy	NCT03349710	Event-free survival (EFS)	15/12/2017
15	Pembrolizumab	PD-1	II	Recurrent and/or metastatic head and neck squamous cell carcinoma	29	Afatinib	NCT03695510	Toxicities and efficacies	24/01/2019
16	Durvalumab	PD-L1	I/II	Head and neck squamous cell carcinoma	33	-	NCT03829007	Treatment regimen	15/04/2019
17	Pembrolizumab	PD-1	II	First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell carcinoma	18	Ulevostinag	NCT04220866	Safety and efficacy	04/03/2020
18	Ipilimumab	CTLA-4	I	Head and neck cancer (Stage III-IVB)	19	Cetuximab with intensity-modulated radiation therapy	NCT01935921	Side effects and dosage regimen	09/04/2013
19	Ipilimumab	CTLA-4	I	Head and neck squamous cell carcinoma	80	Pembrolizumab	NCT01986426	Safety, tolerability, PK, and efficacy	01/11/2013
20	Ipilimumab	CTLA-4	I/II	Advancedstage head and neck squamous cell carcinoma	33	Nivolumab (neoadjuvant to surgery)	NCT03003637	Feasibility and safety	28/02/2017
21	Ipilimumab	CTLA-4	I	Head and neck cancer (Stage IVA-B)	24	Nivolumab with radiotherapy	NCT03162731	Side effects	11/05/2017

2.2. PD-1/GITR Combination

Clinical studies have shown that the combination of anti-GITR and anti-PD-1 antibody therapies can enhance the antitumor activity of T-cells. Among the anti-GITR antibodies, BMS-986156 is an agonistic human IgG1 monoclonal antibody that activates effector T cells and may also reduce or inactivate Tregs ^[23]. A phase I/IIa clinical trial (NCT02598960) evaluated the safety and efficacy of BMS-986156 alone and in combination with the anti-PD-1 antibody, nivolumab, in patients with advanced solid tumors. The trial involved a dose-escalation design, with 66 patients receiving BMS-986156 (10–800 mg) or BMS-986156 (30–800 mg) plus nivolumab (240 mg) every 2 weeks. The study results showed that BMS-986156 ± nivolumab was well tolerated by patients and no dose-limiting toxicity occurred. Significant antitumor activity was seen when BMS-986156 was combined with nivolumab at doses predicted to have biological activity ^[24].

3. Immune Checkpoint Inhibitors in Combination with Other Therapies

3.1. Radiotherapy

Radiotherapy (RT) is widely used to treat solid tumors, with more than 50% of patients receiving this modality. RT has the advantage over chemotherapy in minimizing systemic toxicity ^[25]. When RT is combined with immune checkpoint inhibitors (ICIs), it can potentiate the synergistic effects, where RT contributes to the normalization of the tumor vascular system, enhance the expression of leukocyte adhesion molecules on endothelial cells, and stimulate the secretion of chemokines that attract CD8⁺ T cells ^[26]. ICI treatment is intended for recurrent or metastatic HNSCC that has previously responded to RT, especially for those whose immune cells are being transformed into immunosuppressive and radio-resistant phenotypes. In a phase II study (NCT02641093), the employment of pembrolizumab as adjuvant RT has been shown to improve the survival of patients with locally advanced HNSCC ^[27]. In some patients, following RT can prompt somatic mutations, which can lead to the development of new tumor-associated antigens (TAAs) that can be targeted for more robust immune responses. The concurrent administration of RT and ICIs such as nivolumab (NCT02684253 and NCT03349710) is generally safe with no significant immune-related adverse events on HNSCC ^[28].

3.2. Chemotherapy

Tumor-related antibodies are currently used primarily in combination with chemotherapy due to their limited efficacy as monotherapies ^[29]. Chemotherapy can potentiate the efficacy of immune checkpoint inhibitor (ICI) therapy by promoting the release of neoantigens, modifying the TME through the depletion of Tregs and MDSCs, and reducing PD-L2 expression on DCs and tumor cells. Additionally, chemotherapy (CT) can stimulate APC maturation and increase MHC-I expression ^[30]. One example of an approved combination regimen is the use of pemetrexed and carboplatin chemotherapy with pembrolizumab, where pembrolizumab exhibits minimal overlapping toxicity with the chemotherapeutic agents ^[31]. Other combination regimens under investigation include the use of ipilimumab, paclitaxel, and carboplatin in stage-IV non-small-cell lung carcinoma (NCT02279732) ^[32] and nivolumab with ipilimumab as the standard of care for the first-line treatment of HNSCC (NCT02741570) ^[33]. However, it is important to note that chemotherapy can induce side effects that may interfere with the action mechanisms of ICIs, such as by inhibiting the clonal expansion of effector lymphocytes. Therefore, the potential impact of chemotherapy must be carefully assessed when designing treatment strategies.

References

Sunshine, J.; Taube, J.M. PD-1/PD-L1 inhibitors. Curr. Opin. Pharmacol. 2015, 23, 32–38.
Polverini, P.J.; D’Silva, N.J.; Lei, Y.L. Precision Therapy of Head and Neck Squamous Cell Carcinoma. J. Dent. Res. 2018, 97, 614–621.
Falchook, G.S.; Leidner, R.; Stankevich, E.; Piening, B.; Bifulco, C.; Lowy, I.; Fury, M.G. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J. Immunother. Cancer 2016, 4, 70.
Ferris, R.L.; Blumenschein, G., Jr.; Fayette, J.; Guigay, J.; Colevas, A.D.; Licitra, L.; Harrington, K.; Kasper, S.; Vokes, E.E.; Even, C.; et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N. Engl. J. Med. 2016, 375, 1856–1867.
Harrington, K.J.; Ferris, R.L.; Blumenschein, G., Jr.; Colevas, A.D.; Fayette, J.; Licitra, L.; Kasper, S.; Even, C.; Vokes, E.E.; Worden, F.; et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): Health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017, 18, 1104–1115.
Seiwert, T.Y.; Burtness, B.; Mehra, R.; Weiss, J.; Berger, R.; Eder, J.P.; Heath, K.; McClanahan, T.; Lunceford, J.; Gause, C.; et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol. 2016, 17, 956–965.
Mehra, R.; Seiwert, T.Y.; Gupta, S.; Weiss, J.; Gluck, I.; Eder, J.P.; Burtness, B.; Tahara, M.; Keam, B.; Kang, H.; et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012. Br. J. Cancer 2018, 119, 153–159.
Cohen, E.E.; Soulières, D.; Le Tourneau, C.; Dinis, J.; Licitra, L.; Ahn, M.-J.; Soria, A.; Machiels, J.-P.; Mach, N.; Mehra, R. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet 2019, 393, 156–167.
Burtness, B.; Harrington, K.J.; Greil, R.; Soulières, D.; Tahara, M.; de Castro, G., Jr.; Psyrri, A.; Basté, N.; Neupane, P.; Bratland, A.; et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 2019, 394, 1915–1928.
Latchman, Y.; Wood, C.R.; Chernova, T.; Chaudhary, D.; Borde, M.; Chernova, I.; Iwai, Y.; Long, A.J.; Brown, J.A.; Nunes, R.; et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001, 2, 261–268.
Taube, J.M.; Klein, A.; Brahmer, J.R.; Xu, H.; Pan, X.; Kim, J.H.; Chen, L.; Pardoll, D.M.; Topalian, S.L.; Anders, R.A. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014, 20, 5064–5074.
Yearley, J.H.; Gibson, C.; Yu, N.; Moon, C.; Murphy, E.; Juco, J.; Lunceford, J.; Cheng, J.; Chow, L.Q.M.; Seiwert, T.Y.; et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin. Cancer Res. 2017, 23, 3158–3167.
Chen, D.S.; Irving, B.A.; Hodi, F.S. Molecular pathways: Next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin. Cancer Res. 2012, 18, 6580–6587.
Herbst, R.S.; Soria, J.C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.; McDermott, D.F.; Powderly, J.D.; Gettinger, S.N.; et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515, 563–567.
Colevas, A.D.; Bahleda, R.; Braiteh, F.; Balmanoukian, A.; Brana, I.; Chau, N.G.; Sarkar, I.; Molinero, L.; Grossman, W.; Kabbinavar, F.; et al. Safety and clinical activity of atezolizumab in head and neck cancer: Results from a phase I trial. Ann. Oncol. 2018, 29, 2247–2253.
Migden, M.R.; Rischin, D.; Schmults, C.D.; Guminski, A.; Hauschild, A.; Lewis, K.D.; Chung, C.H.; Hernandez-Aya, L.; Lim, A.M.; Chang, A.L.S.; et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N. Engl. J. Med. 2018, 379, 341–351.
Rischin, D.; Migden, M.R.; Lim, A.M.; Schmults, C.D.; Khushalani, N.I.; Hughes, B.G.M.; Schadendorf, D.; Dunn, L.A.; Hernandez-Aya, L.; Chang, A.L.S.; et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J. Immunother. Cancer 2020, 8, e000775.
Zandberg, D.P.; Algazi, A.P.; Jimeno, A.; Good, J.S.; Fayette, J.; Bouganim, N.; Ready, N.E.; Clement, P.M.; Even, C.; Jang, R.W.; et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur. J. Cancer 2019, 107, 142–152.
Siu, L.L.; Even, C.; Mesia, R.; Remenar, E.; Daste, A.; Delord, J.P.; Krauss, J.; Saba, N.F.; Nabell, L.; Ready, N.E.; et al. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol. 2019, 5, 195–203.
Haddad, R.I.; Harrington, K.; Tahara, M.; Ferris, R.L.; Gillison, M.; Fayette, J.; Daste, A.; Koralewski, P.; Zurawski, B.; Taberna, M.; et al. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. J. Clin. Oncol. 2023, 41, 2166–2180.
Tran, B.; Carvajal, R.D.; Marabelle, A.; Patel, S.P.; LoRusso, P.M.; Rasmussen, E.; Juan, G.; Upreti, V.V.; Beers, C.; Ngarmchamnanrith, G.; et al. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J. Immunother. Cancer 2018, 6, 93.
Schwab, K.S.; Kristiansen, G.; Schild, H.H.; Held, S.E.A.; Heine, A.; Brossart, P. Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab. Case Rep. Oncol. 2018, 11, 17–20.
Shevach, E.M.; Stephens, G.L. The GITR-GITRL interaction: Co-stimulation or contrasuppression of regulatory activity? Nat. Rev. Immunol. 2006, 6, 613–618.
Siu, L.L.; Steeghs, N.; Meniawy, T.; Joerger, M.; Spratlin, J.L.; Rottey, S.; Nagrial, A.; Cooper, A.; Meier, R.; Guan, X.; et al. Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene agonist), alone and in combination with nivolumab in pts with advanced solid tumors. J. Clin. Oncol. 2017, 35, 104.
Trommer, M.; Yeo, S.Y.; Persigehl, T.; Bunck, A.; Grull, H.; Schlaak, M.; Theurich, S.; von Bergwelt-Baildon, M.; Morgenthaler, J.; Herter, J.M.; et al. Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients with Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition. Front. Pharmacol. 2019, 10, 511.
Ko, E.C.; Formenti, S.C. Radiation therapy to enhance tumor immunotherapy: A novel application for an established modality. Int. J. Radiat. Biol. 2019, 95, 936–939.
Guo, S.; Yao, Y.; Tang, Y.; Xin, Z.; Wu, D.; Ni, C.; Huang, J.; Wei, Q.; Zhang, T. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal Transduct. Target. Ther. 2023, 8, 205.
Zappasodi, R.; Merghoub, T.; Wolchok, J.D. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell 2018, 34, 690.
Cruz, E.; Kayser, V. Monoclonal antibody therapy of solid tumors: Clinical limitations and novel strategies to enhance treatment efficacy. Biologics 2019, 13, 33–51.
Qiao, M.; Jiang, T.; Ren, S.; Zhou, C. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand? Clin. Lung Cancer 2018, 19, 1–11.
Garassino, M.C.; Torri, V.; Colombo, M.P.; Sica, A. Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. Cancer Res. 2018, 78, 5729–5730.
Mei, Z.; Huang, J.; Qiao, B.; Lam, A.K. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int. J. Oral Sci. 2020, 12, 16.
Lynch, T.J.; Bondarenko, I.; Luft, A.; Serwatowski, P.; Barlesi, F.; Chacko, R.; Sebastian, M.; Neal, J.; Lu, H.; Cuillerot, J.M.; et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 2012, 30, 2046–2054.

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Oncology; Otorhinolaryngology; Dentistry, Oral Surgery & Medicine

Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

車為王

普拉克庫馬爾比斯瓦斯

阿特庫爾伊斯蘭教

別針 Ju 楚

View Times: 92

Update Date: 12 Mar 2024

Table of Contents

Video Upload Options

Confirm